Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | completed | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 10, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT04502680 | Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients(EMBRAVE-001) | unknown | Phase 2 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | recruiting | Phase 1 / Phase 2 | 20 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03044730 | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT02247037 | Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer | completed | — | 68 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02348320 | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04437160 | Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy | recruiting | Phase 2 | 286 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT04403529 | Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer | unknown | Phase 3 | 200 | Fudan UniversityOTHER | 1 | Jun 1, 2020 | clinicaltrials |
| NCT04405505 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) | unknown | Phase 3 | 332 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01216111 | Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | May 19, 2020 | clinicaltrials |
| NCT04362462 | Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer | unknown | — | 120 | Texas Tech University Health Sciences Center, El PasoOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04225858 | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy(ASICS) | not yet recruiting | N/A | 340 | The Netherlands Cancer InstituteOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT04145947 | Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients | unknown | — | 200 | Peking Union Medical College HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03855358 | A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT03609671 | Emotions Immunology and Breast Cancer | completed | N/A | 17 | Luz A. Venta, MDOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC | suspended | Phase 3 | 375 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01372579 | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03932526 | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer | unknown | Phase 2 | 184 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 60 | PfizerINDUSTRY | 1 | Apr 29, 2019 | clinicaltrials |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03876886 | The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency | unknown | Phase 3 | 200 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)(CLARITY-01) | completed | Phase 1 / Phase 2 | 175 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03799679 | Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer | unknown | Phase 4 | 60 | Fudan UniversityOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03775928 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT00733408 | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | completed | Phase 2 | 59 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment(VICTOR3) | terminated | Phase 2 | 4 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Oct 5, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT03692689 | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | unknown | Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02225470 | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 530 | Eisai Co., Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00986609 | MUC1 Vaccine for Triple-negative Breast Cancer | completed | Early Phase 1 | 29 | Joseph Baar, MD, PhDOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2020source: clinicaltrials